Abstract O42 – Table 1. Analysis results. Note: VISEND: Arm A, HIV RNA <1000 at screening; Arm B, HIV RNA >1000 at screening.
Trial	Arm	Viral failure	Re‐suppression (<50/<200)	Sustained viraemia (>1000)	Sustained viraemia (50 to 999)	Lost to follow‐up
ADVANCE	TAF/FTC/DTG	40/351 (11%)	22/40 (55%)	11/40 (27%)	1/40 (2%)	6/40 (15%)
ADVANCE	TDF/FTC/DTG	43/351 (12%)	25/43 (58%)	6/43 (14%)	5/43 (12%)	7/43 (16%)
ADVANCE	TDF/FTC/EFV	31/351 (9%)	7/31 (23%)	16/31 (52%)	4/31 (13%)	4/31 (13%)
DOLPHIN‐2	TDF/3TC/DTG	41/124 (33%)	14/41 (34%)	10/41 (24%)	8/41 (19%)	9/41 (22%)
DOLPHIN‐2	TDF/3TC/EFV	38/125 (30%)	13/38 (34%)	4/38 (10%)	8/38 (21%)	13/38 (34%)
NAMSAL	TDF/3TC/DTG	48/307 (16%)	29/48 (60%)	10/48 (21%)	3/48 (6%)	6/48 (12%)
NAMSAL	TDF/3TC/EFV	45/306 (15%)	13/45 (29%)	21/45 (47%)	5/45 (11%)	6/45 (13%)
VISEND	TDF/FTC/DTG (A)	10/209 (5%)	5/10 (50%)	2/10 (20%)	1/10 (10%)	2/10 (20%)
VISEND	TAF/FTC/DTG (A)	13/209 (6%)	4/13 (31%)	3/13 (23%)	5/13 (38%)	1/13 (8%)
VISEND	TDF/FTC/DTG (B)	39/208 (19%)	16/39 (41%)	11/39 (28%)	7/39 (18%)	5/39 (13%)
VISEND	TAF/FTC/DTG (B)	26/211 (12%)	9/26 (35%)	8/26 (31%)	3/26 (11%)	6/26 (23%)
VISEND	ZDV/3TC/LPV/r (B)	46/167 (27%)	9/46 (20%)	18/46 (39%)	7/46 (15%)	12/46 (26%)
VISEND	ZDV/3TC/ATV/r (B)	40/197 (20%)	7/40 (17%)	19/40 (47%)	8/40 (20%)	6/40 (15%)